Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar;81(3):337-345.
doi: 10.1007/s00228-024-03799-y. Epub 2024 Dec 27.

Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis

Gang Fan  1   2 , Lin Lin  3 , Hong Zuo  4 , Rui Yan  5 , Chao Xu  6
Affiliations
Meta-Analysis

Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis

Gang Fan et al. Eur J Clin Pharmacol. 2025 Mar.

Abstract

Background: Contrast-induced nephropathy (CIN) is an adverse renal event that occurs following the administration of contrast media for diagnostic procedures or therapeutic angiographic intervention. Nevertheless, there is currently no efficacious and safe agents for the treatment of CIN, except for hydration. We aimed to conduct a meta-analysis to verify the potential nephroprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in the prevention of CIN.

Methods: The PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) databases were searched from their respective inception dates up until 26 August 2024. The "Meta" package of R and Stata software was used for data analysis.

Results: A total of 12 studies were included in the analysis, comprising 11 single-center retrospective studies and one prospective cohort study. Our meta-analysis determined that SGLT2is significantly decrease CIN (odds ratio (OR) 0.39, 95% confidence interval (CI) (0.31, 0.48), P < 0.0001, I2 = 0%) and mortality (OR 0.45, 95% CI (0.26, 0.77), P = 0.0039, I2 = 48%). No notable discrepancy was discerned in continuous renal replacement therapy (CRRT) (OR 0.53, 95% CI (0.15, 1.91), I2 = 0%) or contrast volume (MD - 9.68, 95% CI (- 19.38, 0.03), I2 = 71%).

Conclusion: The present study demonstrated that SGLT2is markedly reduce the incidence of contrast-induced nephropathy in diabetic patients. It is recommended that future large-scale randomized controlled trials (RCTs) are required to confirm these findings and to elucidate further the outcomes in patients without diabetes.

Keywords: Contrast-induced nephropathy; Meta-analysis; Renal function; Sodium-glucose cotransporter 2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

  • Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).
    Paolisso P, Belmonte M, Gallinoro E, Scarsini R, Bergamaschi L, Portolan L, Armillotta M, Esposito G, Moscarella E, Montalto C, de Oliveira EK, Angeli F, Orzalkiewicz M, Fabroni M, Galli V, Baydaroglu N, Di Lenarda F, Policastro P, Terrone C, Ausiello D, Vincelli G, Casenghi M, Scisciola L, Marfella R, Gragnano F, Conte E, Pellegrini D, Ielasi A, Andreini D, Oreglia JA, Calabrò P, Bartorelli AL, Palmerini T, Saia F, Ribichini F, Barbieri M, Vanderheyden M, Pizzi C, Barbato E. Paolisso P, et al. Cardiovasc Diabetol. 2025 May 21;24(1):221. doi: 10.1186/s12933-025-02773-x. Cardiovasc Diabetol. 2025. PMID: 40399991 Free PMC article.

References

    1. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL et al (2024) 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 149:e347–e913 - DOI - PubMed
    1. Mensah GA, Fuster V, Murray CJL, Roth GA, Global Burden of Cardiovascular D, Risks C (2023) Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol 82:2350–473.
    1. Faro DC, Laudani C, Agnello FG, Ammirabile N, Finocchiaro S, Legnazzi M et al (2023) Complete percutaneous coronary revascularization in acute coronary syndromes with multivessel coronary disease: a systematic review. JACC Cardiovasc Interv 16:2347–2364 - DOI - PubMed
    1. Kusirisin P, Chattipakorn SC, Chattipakorn N (2020) Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med 18:400 - DOI - PubMed - PMC
    1. Writing Committee M, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM et al (2022) 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:e21–e129 - DOI

MeSH terms

Substances

LinkOut - more resources